Killick MA - Search Results

1

Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.

Moshoette T, Ali SA, Papathanasopoulos MA, Killick MA. Moshoette T, et al. Among authors: killick ma. Retrovirology. 2019 Nov 8;16(1):31. doi: 10.1186/s12977-019-0493-y. Retrovirology. 2019. PMID: 31703699 Free PMC article.

2

HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6.

Moshoette T, Papathanasopoulos MA, Killick MA. Moshoette T, et al. Among authors: killick ma. Virol J. 2022 Sep 7;19(1):143. doi: 10.1186/s12985-022-01876-1. Virol J. 2022. PMID: 36071449 Free PMC article.

3

Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).

Killick MA, Grant ML, Cerutti NM, Capovilla A, Papathanasopoulos MA. Killick MA, et al. Vaccine. 2015 Nov 17;33(46):6298-306. doi: 10.1016/j.vaccine.2015.09.056. Epub 2015 Oct 1. Vaccine. 2015. PMID: 26432912

4

Covalent binding of human two-domain CD4 to an HIV-1 subtype C SOSIP.664 trimer modulates its structural dynamics.

Tumba NL, Naicker P, Stoychev S, Killick MA, Owen GR, Papathanasopoulos MA. Tumba NL, et al. Among authors: killick ma. Biochem Biophys Res Commun. 2022 Jul 5;612:181-187. doi: 10.1016/j.bbrc.2022.04.101. Epub 2022 Apr 26. Biochem Biophys Res Commun. 2022. PMID: 35550505

5

Immunization with HIV-1 trimeric SOSIP.664 BG505 or founder virus C (FVC_Env) covalently complexed to two-domain CD4^S60C elicits cross-clade neutralizing antibodies in New Zealand white rabbits.

Tumba NL, Owen GR, Killick MA, Papathanasopoulos MA. Tumba NL, et al. Among authors: killick ma. Vaccine X. 2022 Sep 30;12:100222. doi: 10.1016/j.jvacx.2022.100222. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36262212 Free PMC article.

6

Generation and characterization of an HIV-1 subtype C transmitted and early founder virus consensus sequence.

Killick M, Capovilla A, Papathanasopoulos MA. Killick M, et al. AIDS Res Hum Retroviruses. 2014 Oct;30(10):1001-5. doi: 10.1089/AID.2014.0042. Epub 2014 Aug 11. AIDS Res Hum Retroviruses. 2014. PMID: 25025284 Free PMC article.

7

Disulfide reduction in CD4 domain 1 or 2 is essential for interaction with HIV glycoprotein 120 (gp120), which impairs thioredoxin-driven CD4 dimerization.

Cerutti N, Killick M, Jugnarain V, Papathanasopoulos M, Capovilla A. Cerutti N, et al. J Biol Chem. 2014 Apr 11;289(15):10455-10465. doi: 10.1074/jbc.M113.539353. Epub 2014 Feb 18. J Biol Chem. 2014. PMID: 24550395 Free PMC article.

8

Thioredoxin (Trx1) regulates CD4 membrane domain localization and is required for efficient CD4-dependent HIV-1 entry.

Moolla N, Killick M, Papathanasopoulos M, Capovilla A. Moolla N, et al. Biochim Biophys Acta. 2016 Sep;1860(9):1854-63. doi: 10.1016/j.bbagen.2016.05.030. Epub 2016 May 24. Biochim Biophys Acta. 2016. PMID: 27233453

9

Stabilization of HIV-1 gp120-CD4 receptor complex through targeted interchain disulfide exchange.

Cerutti N, Mendelow BV, Napier GB, Papathanasopoulos MA, Killick M, Khati M, Stevens W, Capovilla A. Cerutti N, et al. Among authors: killick m. J Biol Chem. 2010 Aug 13;285(33):25743-52. doi: 10.1074/jbc.M110.144121. Epub 2010 Jun 10. J Biol Chem. 2010. PMID: 20538591 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters